


Existence of endemic viruses and their likely zoonotic transmission bells an alarm for development of population specific vaccines. Computational prediction of neoantigens not only serves the purpose of vaccine design against viruses but also for personalised immunogenic therapy.

Entire study is performed over public GALAXY server - GALAXY Europe - <https://usegalaxy.eu/>. Schematic execution of the workflow is as follows.



We can incorporate and try various options of available aligners and variant callers like BWA-MEM, Bowtie2, STAR, HISAT2, GATK, VARSCAN, FreeBayes etc. while forming GALAXY workflows.

Genomic variant detection (results are combined together)	<a href="https://usegalaxy.eu/u/ambarishk/w/gatk4">https://usegalaxy.eu/u/ambarishk/w/gatk4</a>
	<a href="https://usegalaxy.eu/u/ambarishk/w/varscan">https://usegalaxy.eu/u/ambarishk/w/varscan</a>
HLA typing and neoantigen prediction	<a href="https://usegalaxy.eu/u/ambarishk/w/neo-antigen-prediction">https://usegalaxy.eu/u/ambarishk/w/neo-antigen-prediction</a>

Table-01: Shared and published GALAXY workflows incorporated into the present study.

Preliminary result is based upon SARS-CoV-2 infected human RNASEQ paired-end illumina reads obtained from SARS-CoV-2 infected Wuhan, China population. SRR accession - [SRR11454612](https://www.ncbi.nlm.nih.gov/srr/SRR11454612). Tabulated results are top ranked neoantigens generated from mitochondrially encoded cytochrome c oxidase I.

allele	length	peptide	ic50	percentile_rank
HLA-A*24:02	9	TYAKIHFTI	6.6	0.02
HLA-A*24:02	9	LYQHLEWFF	14.4	0.03

Table-02: Predicted MHC class I neoantigen using netmhcpan method.

allele	length	peptide	ic50	rank
HLA-DRB1*15:01	12	YILILPGFGMIS	67.19	0.1
HLA-DRB1*15:01	12	VYILILPGFGMI	67.33	0.1

Table-03: Predicted MHC class II neoantigens using netmhcpan method.

allele	length	peptide	proteasome_score	tap_score	mhc_score	processing_score	total_score	ic50_score
HLA-A* 24:02	9	LYQHL FWFF	1.4661 75	1.2064 229672	-1.3159 703454 6	2.6725 979672	1.3566 276217 4	20.7
HLA-A* 24:02	9	MFIGV NLTF	1.4329 85	1.2271 636708	-1.4487 063199 1	2.6601 486708	1.2114 423508 9	28.1

Table-04: Predicted MHC I processing using netmhcpan method

Position	Residue	Start	End	Peptide	Score
3	A	1	5	MFADR	0.854
4	D	2	6	FADRW	0.926

Table-05: Antibody epitope prediction using Chau-Fasman method

Shared GALAXY history - <https://usegalaxy.eu/u/ambarishk/h/neo-antigen-prediction>

Extended work will include development of a workbench as a dedicated GALAXY server for neoantigen prediction and antigenicity analysis as well as generation of results for all virus infections whose vaccines are under development and diseases requiring personalised neoantigen therapy. It will be an effective computational platform for population specific and personalised neoantigen therapy. As a collaborative and shared effort we will be working along with Galaxy for proteomics (Galaxy-P) team at the University of Minnesota, USA. Associated aspects with computational prediction of neoantigens over GALAXY are automation, reproducibility, time and cost-effectiveness.

## References

[1] Roudko V, Greenbaum B, Bhardwaj N. Computational Prediction and Validation of Tumor-Associated Neoantigens. *Front Immunol.* 2020;11:27. Published 2020 Jan 24. doi:10.3389/fimmu.2020.00027

[2] Enis Afgan, Dannon Baker, Bérénice Batut, Marius van den Beek, Dave Bouvier, Martin Čech, John Chilton, Dave Clements, Nate Coraor, Björn Grüning, Aysam Guerler, Jennifer Hillman-Jackson, Vahid Jalili, Helena Rasche, Nicola Soranzo, Jeremy Goecks, James Taylor, Anton Nekrutenko, and Daniel Blankenberg. **The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update**, *Nucleic Acids Research*, Volume 46, Issue W1, 2 July 2018, Pages W537–W544, doi:10.1093/nar/gky379

